169 related articles for article (PubMed ID: 36269747)
21. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
22. Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection.
Majeed AY; Zulkafli NES; Ad'hiah AH
Immunol Lett; 2023 Aug; 260():24-34. PubMed ID: 37339685
[TBL] [Abstract][Full Text] [Related]
23. Elevated Cytokine Levels in the Aqueous Humor of Eyes With Bullous Keratopathy and Low Endothelial Cell Density.
Yamaguchi T; Higa K; Suzuki T; Nakayama N; Yagi-Yaguchi Y; Dogru M; Satake Y; Shimazaki J
Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):5954-5962. PubMed ID: 27820951
[TBL] [Abstract][Full Text] [Related]
24. Cytokine profiling in patients with hepatic glycogen storage disease: Are there clues for unsolved aspects?
Colonetti K; Pinto E Vairo F; Siebert M; Nalin T; Poloni S; Fernando Wurdig Roesch L; Fischinger Moura de Souza C; Cabral Pinheiro F; Vanessa Doederlein Schwartz I
Cytokine; 2023 Feb; 162():156088. PubMed ID: 36462220
[TBL] [Abstract][Full Text] [Related]
25. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].
Zhu HL; DU Q; Chen WL; Zuo XX; Li QZ; Liu SJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):716-722. PubMed ID: 31420628
[TBL] [Abstract][Full Text] [Related]
26. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
27. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Holch JW; Held S; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; von Einem JC; Michl M; Heinemann V
Ann Oncol; 2020 Jan; 31(1):72-78. PubMed ID: 31912799
[TBL] [Abstract][Full Text] [Related]
28. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
Berger MD; Stintzing S; Heinemann V; Cao S; Yang D; Sunakawa Y; Matsusaka S; Ning Y; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Zhang W; Cremolini C; Falcone A; Loupakis F; Lenz HJ
Clin Cancer Res; 2018 Feb; 24(4):784-793. PubMed ID: 29208668
[No Abstract] [Full Text] [Related]
29. Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients.
Monserrat J; Gómez-Lahoz A; Ortega MA; Sanz J; Muñoz B; Arévalo-Serrano J; Rodríguez JM; Gasalla JM; Gasulla Ó; Arranz A; Fortuny-Profitós J; Mazaira-Font FA; Teixidó Román M; Martínez-A C; Balomenos D; Asunsolo A; Álvarez-Mon M; On Behalf Of The Covid-Hupa Group
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142255
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of Inflammatory Mediators in the Normal Pericardial Fluid.
El-Diasty MM; Rodríguez J; Pérez L; Eiras S; Fernández AL
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203327
[TBL] [Abstract][Full Text] [Related]
31. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
Lereclus E; Tout M; Girault A; Baroukh N; Caulet M; Borg C; Bouché O; Ternant D; Paintaud G; Lecomte T; Raoul W
BMC Cancer; 2017 Mar; 17(1):220. PubMed ID: 28347290
[TBL] [Abstract][Full Text] [Related]
32. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
33. Iris Damage Is Associated With Elevated Cytokine Levels in Aqueous Humor.
Aketa N; Yamaguchi T; Suzuki T; Higa K; Yagi-Yaguchi Y; Satake Y; Tsubota K; Shimazaki J
Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO42-BIO51. PubMed ID: 28475702
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada.
Jerzak KJ; Berry S; Ko YJ; Earle C; Chan KK
Int J Cancer; 2017 May; 140(9):2162-2167. PubMed ID: 28220486
[TBL] [Abstract][Full Text] [Related]
35. Yersinia enterocolitica invasin protein triggers differential production of interleukin-1, interleukin-8, monocyte chemoattractant protein 1, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor alpha in epithelial cells: implications for understanding the early cytokine network in Yersinia infections.
Kampik D; Schulte R; Autenrieth IB
Infect Immun; 2000 May; 68(5):2484-92. PubMed ID: 10768935
[TBL] [Abstract][Full Text] [Related]
36. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
38. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Antonetti P; Fargnoli MC; Porzio G; Salvatore L; Filippi R; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Dell'Aquila E; Lombardi P; Keränen SR; Depetris I; Giampieri R; Morelli C; De Tursi M; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Cortellini A; Pensieri MV; Ficorella C; Ferri C; Parisi A
Support Care Cancer; 2022 Mar; 30(3):2455-2465. PubMed ID: 34779921
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
